biologic

Riastap

Fibrinogen Concentrate (Human)

Loss of exclusivityDecember 2037projected — 12-year biologic exclusivity estimate
CompanyCSL Behring GmbH

Drug detail

Brand nameRiastap
Active ingredientFibrinogen Concentrate (Human)
Strength1800-2600MG
Dosage formFor Injection
RouteIntravenous
ModalityBiologic
FDA approvalDecember 2025
Marketing statusRx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Riastap patent cliff — loss of exclusivity December 2037 | CliffBio